Cost Utility Analysis of Erythropoietin for Anemia Treatment in Hemodialysis Patients

NCT01049711 | Completed

• 1 other identifier: CUAEPO
• Study Type: observational
• Target: 152
• Locations: 1 country
• Sites: 1

Brief Summary

To study the cost utility analysis of Erythropoietin (EPO) for maintaining the different hemoglobin (Hb) target levels in anemic hemodialysis patient in routine clinical practice.

Conditions

Chronic Renal Failure

Keywords

erythropoietin; hemodialysis; cost utility; incremental cost-effectiveness ratio; Quality adjusted life year; quality of life

Outcome Measures

Primary Outcomes (2)

• The utility scores of hemodialysis (HD) patients who use EPO to maintain the Hb target level.

  1 year

• Cost of HD patients who use EPO to maintain the Hb target level.

  1 year

Secondary Outcomes (1)

• The incremental cost-effectiveness ratio (calculated as the ratio between the incremental differences in costs and QALYs associated with 2 alternative treatments) of EPO at the different Hb target levels in HD patients in routine clinical practice.

  lifetime horizon (Economic evaluation term)

Study Arms (1)

erythropoietin

Drug: erythropoietin

Interventions

erythropoietin DRUG

erythropoietin

Eligibility Criteria

• Age: 18 Years - 85 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

HD patients use EPO at least 6 months with titration of EPO therapy is permitted

You may qualify if:

• Patients use EPO at least 6 months with titration of EPO therapy is permitted

You may not qualify if:

• Patients under 18 years old.
• Patients who have blood transfusion for anemic treatment within 6 months before EPO treatment and before the study starts
• Patients who change the modality of dialysis
• Patients who switch to other anemia treatment method between the study
• Patients who cannot answer the questionnaire and are not willing to participate in the study

Sponsors & Collaborators

• Mahidol University: lead

Study Sites (1)

Siriraj Hospital

Bangkok, Thailand

Location

MeSH Terms

Conditions

Kidney Failure, Chronic

Interventions

Erythropoietin

Condition Hierarchy (Ancestors)

Renal Insufficiency, Chronic; Renal Insufficiency; Kidney Diseases; Urologic Diseases; Female Urogenital Diseases; Female Urogenital Diseases and Pregnancy Complications; Urogenital Diseases; Male Urogenital Diseases; Chronic Disease; Disease Attributes; Pathologic Processes; Pathological Conditions, Signs and Symptoms

Intervention Hierarchy (Ancestors)

Colony-Stimulating Factors; Glycoproteins; Glycoconjugates; Carbohydrates; Hematopoietic Cell Growth Factors; Cytokines; Intercellular Signaling Peptides and Proteins; Peptides; Amino Acids, Peptides, and Proteins; Proteins; Biological Factors

Study Officials

• Tanita Thaweethamcharoen, Ph.D

  Faculty of Medicine, Mahidol University

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: observational
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: January 11, 2010
• First Posted: January 14, 2010
• Study Start: November 1, 2009
• Primary Completion: February 1, 2010
• Study Completion: September 1, 2010
• Last Updated: September 29, 2015

Record last verified: 2015-09

Locations

TH (1)